kiniksa
announces
orphan
drug
designation
mavrilimumab
treatment
giant
cell
arteritis
hamilton
bermuda
globe
newswire
kiniksa
pharmaceuticals
nasdaq
knsa
kiniksa
biopharmaceutical
company
focused
discovering
acquiring
developing
commercializing
therapeutic
medicines
patients
significant
unmet
medical
need
today
announced
food
drug
administration
fda
granted
orphan
drug
designation
mavrilimumab
treatment
giant
cell
arteritis
gca
mavrilimumab
monoclonal
antibody
inhibitor
targeting
granulocyte
macrophage
colony
stimulating
factor
receptor
alpha
pleased
announce
fda
granted
orphan
drug
designation
mavrilimumab
treatment
gca
said
sanj
patel
chief
executive
officer
chairman
board
kiniksa
data
phase
study
mavrilimumab
gca
expected
fourth
quarter
live
webcast
kiniksa
presentation
morgan
stanley
annual
global
healthcare
conference
wednesday
september
eastern
daylight
time
company
provide
update
key
activities
relating
rilonacept
mavrilimumab
vixarelimab
presentation
accessible
investors
media
section
company
website
replay
webcast
available
kiniksa
website
days
following
conference
orphan
drug
designation
fda
grants
orphan
drug
designation
status
products
treat
rare
diseases
providing
incentives
sponsors
developing
drugs
biologics
fda
defines
rare
diseases
affecting
fewer
people
time
designation
orphan
drug
designation
entitles
party
financial
incentives
opportunities
grant
funding
towards
clinical
trial
costs
tax
advantages
waivers
product
orphan
designation
subsequently
receives
first
fda
approval
disease
condition
designation
product
entitled
orphan
drug
exclusivity
means
fda
may
approve
applications
market
drug
indication
seven
years
date
approval
except
limited
circumstances
additionally
orphan
drug
designation
waives
requirement
conduct
pediatric
studies
product
disease
designated
giant
cell
arteritis
giant
cell
arteritis
chronic
inflammatory
disease
arteries
cranial
giant
cell
arteritis
typically
presents
headache
jaw
claudication
well
constitutional
symptoms
fever
fatigue
acute
events
include
permanent
vision
loss
diminished
blood
flow
eye
large
vessel
form
giant
cell
arteritis
affects
branches
aorta
supplying
trunk
limbs
currently
one
treatment
giant
cell
arteritis
adjunct
steroid
taper
mavrilimumab
mavrilimumab
investigational
monoclonal
antibody
targets
granulocyte
macrophage
colony
stimulating
factor
receptor
alpha
mavrilimumab
dosed
patients
rheumatoid
arthritis
phase
clinical
studies
europe
achieved
primary
endpoints
efficacy
safety
kiniksa
lead
indication
mavrilimumab
giant
cell
arteritis
gca
inflammatory
disease
arteries
kiniksa
also
evaluating
mavrilimumab
pneumonia
hyperinflammation
fda
granted
orphan
drug
designation
mavrilimumab
gca
kiniksa
kiniksa
biopharmaceutical
company
focused
discovering
acquiring
developing
commercializing
therapeutic
medicines
patients
suffering
debilitating
diseases
significant
unmet
medical
need
kiniksa
product
candidates
rilonacept
mavrilimumab
vixarelimab
based
strong
biologic
rationale
validated
mechanisms
target
underserved
conditions
offer
potential
differentiation
pipeline
assets
designed
modulate
immunological
pathways
implicated
across
spectrum
diseases
information
please
visit
statements
press
release
contains
statements
within
meaning
private
securities
litigation
reform
act
cases
identify
forward
looking
statements
terms
may
expect
plan
anticipate
could
intend
target
project
contemplate
believe
estimate
predict
potential
continue
negative
terms
similar
expressions
although
statements
contain
identifying
words
statements
contained
press
release
relate
matters
historical
fact
considered
statements
including
without
limitation
statements
regarding
belief
mavrilimumab
targets
cytokine
may
responsible
critical
pathological
steps
gca
rare
disease
significant
unmet
need
timing
data
phase
study
mavrilimumab
gca
belief
product
candidates
offer
potential
differentiation
statements
based
management
current
expectations
statements
neither
promises
guarantees
involve
known
unknown
risks
uncertainties
important
factors
may
cause
actual
results
performance
achievements
materially
different
future
results
performance
achievements
expressed
implied
statements
including
without
limitation
following
potential
inability
replicate
later
clinical
trials
positive
final
data
earlier
clinical
trials
protocols
studies
impact
additional
data
us
companies
potential
undesirable
side
effects
caused
product
candidates
potential
inability
demonstrate
safety
efficacy
satisfaction
applicable
regulatory
authorities
reliance
third
parties
manufacture
product
candidates
drug
substance
drug
product
shortages
reliance
third
parties
conduct
research
clinical
trials
certain
regulatory
activities
product
candidates
potential
impact
pandemic
measures
taken
response
pandemic
changes
operating
plan
funding
requirements
existing
new
competition
ability
attract
retain
qualified
personnel
important
factors
discussed
caption
risk
factors
quarterly
report
form
filed
securities
exchange
commission
sec
may
august
reports
subsequently
filed
sec
could
cause
actual
results
differ
materially
indicated
statements
made
press
release
statements
represent
management
estimates
date
press
release
may
elect
update
statements
point
future
disclaim
obligation
even
subsequent
events
cause
views
change
statements
relied
upon
representing
views
date
subsequent
date
press
release
every
second
counts
kiniksa
investor
media
contact
mark
ragosa
mragosa
